Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Shares Outstanding (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Shares Outstanding over the past 15 years, most recently at $37.0 million for Q2 2025.

  • Quarterly results put Shares Outstanding at $37.0 million for Q2 2025, up 21.15% from a year ago — trailing twelve months through May 2025 was $37.0 million (up 21.15% YoY), and the annual figure for FY2025 was $37.0 million, up 21.15%.
  • Shares Outstanding for Q2 2025 was $37.0 million at Lifecore Biomedical, Inc. \De\, roughly flat from $37.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding for LFCR hit a ceiling of $37.0 million in Q2 2025 and a floor of $29.3 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $30.3 million (2023), compared with a mean of $31.2 million.
  • Biggest five-year swings in Shares Outstanding: grew 0.37% in 2021 and later increased 21.41% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Shares Outstanding stood at $29.5 million in 2021, then grew by 2.77% to $30.3 million in 2022, then rose by 0.53% to $30.5 million in 2023, then rose by 21.41% to $37.0 million in 2024, then grew by 0.12% to $37.0 million in 2025.
  • The last three reported values for Shares Outstanding were $37.0 million (Q2 2025), $37.0 million (Q1 2025), and $37.0 million (Q4 2024) per Business Quant data.